Skip to main navigation
Go to Daré Bioscience homepage
  • About
  • Pipeline
  • Consumers
  • Investors
  • Contact Us
    • Investors
    • Press releases
    • Presentations, Events & Webcasts
    • Stock information
    • Financial Information
    • Corporate governance
    • Form 8937
    • Contact

    Press Releases

    06-04-2026
    Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
    05-26-2026
    Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
    05-18-2026
    Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
    05-14-2026
    Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
    05-12-2026
    Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
    05-07-2026
    Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
    03-26-2026
    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
    03-23-2026
    On National Viagra Day, Women Finally Claim Their Turn:
    03-20-2026
    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
    03-16-2026
    Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
    • Current page 1
    • Page 2
    • Next page ›
    • Last page »
    Displaying 1 - 10 of 13
    • Request email alerts |
    • Print this page |
    • Search investor site

    © 2026 by Daré Bioscience | Daré Bioscience® is a registered trademark of Daré Bioscience, Inc.

    • Privacy Policy|
    • Terms of Service|
    • COI Policy

    Scroll to top